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PDGFβ-receptor targeted drug carrier
Protein delivery
in vitro in vivo correlation
Liver ﬁbrosis
A B S T R A C T
Liver ﬁbrogenesis is associated with excessive production of extracellular matrix by myoﬁbroblasts that often
leads to cirrhosis and consequently liver dysfunction and death. Novel protein-based antiﬁbrotic drugs show
high speciﬁcity and eﬃcacy, but their use in the treatment of ﬁbrosis causes a high burden for patients, since
repetitive and long-term parenteral administration is required as most proteins and peptides are rapidly cleared
from the circulation. Therefore, we developed biodegradable polymeric microspheres for the sustained release of
proteinaceous drugs. We encapsulated the drug carrier pPB-HSA, which speciﬁcally binds to the PDGFβR that is
highly upregulated on activated myoﬁbroblasts, into microspheres composed of hydrophilic multi-block copo-
lymers composed of poly(L-lactide) and poly ethylene glycol/poly(ϵ-caprolactone), allowing diﬀusion-controlled
release. Firstly, we estimated in mice with acute ﬁbrogenesis induced by a single CCl4 injection the half-life of
I125-labeled pPB-HSA at 40 min and conﬁrmed the preferential accumulation in ﬁbrotic tissue. Subsequently, we
determined in the Mdr2−/− mouse model of advanced biliary liver ﬁbrosis how the subcutaneously injected
microspheres released pPB-HSA into both plasma and ﬁbrotic liver at 24 h after injection, which was maintained
for six days. Although the microspheres still contained protein at day seven, pPB-HSA plasma and liver con-
centrations were decreased. This reduction was associated with an antibody response against the human al-
bumin-based carrier protein, which was prevented by using a mouse albumin-based equivalent (pPB-MSA). In
conclusion, this study shows that our polymeric microspheres are suitable as sustained release formulation for
targeted protein constructs such as pPB-HSA. These formulations could be applied for the long-term treatment of
chronic diseases such as liver ﬁbrosis.
1. Introduction
Sustained release drug delivery systems are increasingly used as a
patient-friendly alternative to conventional dosage forms [1,2]. When
controlling the release rate of a drug its therapeutic actions can be
drastically improved by obtaining prolonged release associated with
less ﬂuctuations in plasma concentration. This avoids peak levels and
reduces side eﬀects. This way, the bioavailability, eﬃcacy and safety of
drugs can be signiﬁcantly enhanced [2,3]. One such drug delivery
system is microspheres, that allows ﬂexible dosing of the drug [4]. This
approach is particularly interesting for application of potent protein-
based therapeutics, as the administration frequency can be largely
reduced as compared to intravenous administration. Moreover, when
encapsulated in polymeric microparticles, the biopharmaceutical can
be eﬀectively protected from degradation induced by biological con-
ditions or enzymes [2,5].
In the treatment of chronic diseases such as ﬁbrosis, the application
of sustained release formulations like microspheres for antiﬁbrotic
drugs could signiﬁcantly improve patient compliance and therapeutic
eﬃcacy, especially since the expected treatment would be long-term.
Hepatic ﬁbrosis is a progressive, pathological condition aﬀecting mil-
lions of people worldwide [6]. Following chronic liver injury, in-
ﬂammatory and bile ductular cells release a variety of mediators that
provoke the activation of ﬁbroblasts and hepatic stellate cells to
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myoﬁbroblasts, which start to produce extracellular matrix (ECM)
components, especially ﬁbrillar collagens in a chronic would healing
reaction. In cirrhosis, which represents an advanced stage of ﬁbrosis,
the liver vascular architecture gets progressively distorted and func-
tional parenchymal cells are ultimately replaced by abundant ECM,
which causes liver failure, and ﬁnally decompensated cirrhosis [7–9].
For some patients with cirrhosis, liver transplantation or treatment
with a new generation of highly eﬀective antiviral agents against
Hepatitis B and C may be a curative treatment, however there is still an
urge for eﬀective antiﬁbrotic treatments to fulﬁll the needs of all pa-
tients [10–12]. Many promising new drugs are biological-based, such as
growth factors, cytokines and monoclonal antibodies. A class of ther-
apeutic proteins currently under development is the fusion proteins,
including biologic-based drugs modiﬁed with targeting moieties
[13,14]. Such proteins are particularly interesting as their therapeutic
eﬀects can be increased while avoiding side eﬀects [15]. The platelet-
derived growth factor beta receptor (PDGFβR) is abundantly expressed
on myoﬁbroblasts in ﬁbrotic tissues with high ﬁbrogenic activity
[16,17], and therefore its expression was exploited as a potential target
for the cell-speciﬁc delivery of antiﬁbrotic drugs. A carrier protein with
high aﬃnity for the PDGFβR was designed, composed of an albumin
core with multiple cyclic PDGFβR-recognizing peptides (pPB) binding
the PDGFβR. Previous studies have shown that the carrier, referred to
as pPB-HSA, selectively bound to the PDGFβR and accumulated in ﬁ-
brogenic cells in the ﬁbrotic liver which highly expressed the PDGFβR.
The carrier itself did neither elicit an antiﬁbrotic eﬀect nor induced
proliferation of ﬁbroblasts [18].
Because many therapeutic proteins have poor in vivo pharmacoki-
netic properties as reﬂected by relatively short in vivo plasma half-lives,
we developed a microsphere formulation containing pPB-HSA that
ensures gradual protein release over a period of 14 days, which could
be suitable for therapeutic application of other large therapeutic pro-
teins as well. A blend of two biodegradable semi-crystalline multi-block
co-polymers, composed of crystalline blocks of poly(L-lactide) (PLLA)
and amorphous blocks of poly ethylene glycol (PEG) and poly(ϵ-ca-
prolactone) (PCL), was used as a matrix for these microspheres. Whilst
mostly polymers are used that show degradation-controlled release
[19], e.g. poly (lactic-co-glycolic acid), these particular polymers pro-
vided diﬀusion-controlled release of proteins, caused by swelling of the
PEG blocks by water uptake [20]. Disadvantage of degradation-con-
trolled release is that the degradation products of the polymer are
usually incompatible with proteins [21].
We previously showed proof of concept of eﬀective release of drug
carriers from microspheres composed of these multi-block copolymers
in the unilateral ureter obstruction model for kidney ﬁbrosis. In that
study, we demonstrated the release of pPB-HSA from subcutaneously
injected microspheres into plasma and the subsequent localization of
this drug carrier in the ﬁbrotic kidney 7 days after administration of the
microspheres [22]. Although we were able to demonstrate protein re-
lease after 7 days, the in vivo release characteristics and the correlation
with the in vivo kinetics remained undeﬁned.
In the present study, we therefore further explored the applicability
of these microspheres as a sustained controlled release formulation for
biologicals. For this, we examined the in vivo kinetic behavior of pPB-
HSA in two diﬀerent mouse models for liver ﬁbrosis that display high
and speciﬁc PDGFβR-expression, i.e. the acute CCl4 model and the
Mdr2−/− model. In the acute CCl4 model, we used I125-labeled pPB-
HSA to determine pharmacokinetic parameters and tissue distribution
of this carrier protein. Subsequently, the in vivo release proﬁle of pPB-
HSA from microspheres was determined in the chronic Mdr2−/−
model.
2. Materials and methods
2.1. Pharmacokinetics of I125-labeled pPB-HSA
The experimental protocols for animal studies with the CCl4-model
were approved by the Animal Ethical Committee of the University of
Groningen (The Netherlands). Male C57BL/6 mice (20–22 g) were ob-
tained from Envigo (Horst, The Netherlands). Animals received ad li-
bitum normal diet with a 12 h light/dark cycle. Mice (n= 12) received
a single injection of CCl4 (Sigma Aldrich, Zwijndrecht, The
Netherlands) diluted in olive oil (0.5 mg/kg) intraperitoneally. After
24 h, mice were intravenously injected with tracer amounts of I125-la-
beled pPB-HSA (1 ∗ 105–5 ∗ 105 counts per minute (CPM) in PBS) and
sacriﬁced after 10, 30 or 60 min (n= 4 per time point), after which
blood and all organs were collected to assess radioactivity [18]. pPB-
HSA was labeled with 125I as described before [18].
2.2. Synthesis of polymers and proteins
The two multi-block co-polymers were synthesized as described
before from the prepolymers PLLA and PCL-PEG-PCL [22,23]. In short,
[PLLA] was chain-extended with [PCL-PEG1000-PCL or PCL-PEG3000-
PCL] using 1,4-butanediisocyanate (Actu-all Chemicals B.V., Oss, The
Netherlands), to prepare the multi-block co-polymers [PCL-PEG1000-
PCL]-[PLLA] (50/50 weight ratio) and [PCL-PEG3000-PCL]/[PLLA] (30/
70 weight ratio). For this, [PLLA] and [PCL-PEG1000-PCL or PCL-
PEG3000-PCL] were dissolved in dry 1,4-dioxane (80 °C, 30 wt-% solu-
tion), 1,4-butanediisocyanate was added and the reaction mixture
stirred for 20 h. The reaction mixture was frozen and freeze-dried at
30 °C shelf temperature to remove 1,4-dioxane.
The proteins pPB-HSA and pPB-MSA were synthesized as described
before [24]. Brieﬂy, N-γ-maleimidobutyryl-oxysuccinimide ester was
added to either human (puriﬁed from Cealb®, Sanquin, Amsterdam, The
Netherlands) or mouse serum albumin (Equitech-Bio Inc., Kerville, TX,
USA). Next, N-succinimidyl S-acetylthioacetate (SATA)-modiﬁed pPB
(C*SRNLIDC*, Ansynth Service B.V., Roosendaal, The Netherlands) and
activation solution (containing hydroxylamine and EDTA) were added.
After extensive dialysis, the monomeric product was freeze-dried and
stored at −20 °C.
2.3. Production and characterization of microspheres
Microspheres were produced using a similar water-in-oil-in-water
double emulsiﬁcation evaporation method as described previously
[22]. In brief, the multi-block co-polymers were dissolved in di-
chloromethane in a 50:50 weight ratio. For the primary emulsion, PBS
(control) or a solution of 80 mg/mL protein (HSA; or pPB-HSA and
HSA, or the mouse equivalents, in a 3:2 ratio) was added to the ﬁltered
polymer solution to obtain 5 wt-% theoretical protein load and homo-
genized. For the secondary emulsion, the primary emulsion was added
to 4 wt-% poly vinyl alcohol (Sigma Aldrich) + 5 wt-% NaCl solution in
water under stirring. The hardened microspheres were collected by
ﬁltration, washed and freeze dried.
Microspheres were characterized for morphology by scanning
electron microscopy, for particle size distribution by laser diﬀraction,
and for protein content and in vitro release of HSA, pPB-HSA or pPB-
MSA as described by [22]. Scanning electron microscopy imaging was
performed at an acceleration voltage of 10 kV (JSM-6460 microscope,
Jeol, Tokio, Japan). Samples were ﬁxed on an aluminum sample holder
using double sided adhesive carbon tape and sputter coated with 10 nm
of gold. The particle size distributions of microspheres were determined
with laser diﬀraction and subsequently the span of the particle size
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where X10, X50 and X90 represent the volume percentages of particles
(10%, 50% and 90% undersize, respectively). The in vitro release was
measured in triplicate by a sample-and-replace method. Brieﬂy, 10 mg
of microspheres were suspended in 1.0 mL release buﬀer (100 mM so-
dium phosphate buﬀer, containing NaCl, Tween 80 and NaN3). Samples
of 800 μL were taken at predetermined time points and replaced by
fresh buﬀer. Protein concentrations were determined with BCA assay
and an in-house developed ELISA for pPB-HSA (see section ELISA). The
protein content of the remaining microspheres was determined using
BCA assay as described before [22] and was used to calculate the en-
capsulation eﬃciency (EE), which is deﬁned as the weight of en-
capsulated protein (i.e. HSA, pPB-HSA or pPB-MSA) divided by the
weight of total protein used.
2.4. Pharmacokinetics of pPB-HSA from microspheres
Studies with the Mdr2−/− mouse model were approved by the
Animal Ethical Committee of the State of Rhineland Palatinate. Female
FVB mice (n= 8) were obtained from Jackson Laboratory (Jackson
Laboratory, Bar Harbor, ME, USA) and FVB Mdr2−/− mice (n= 24)
(20–28 g) were bred in homozygosity at the Institute of Translational
Immunology at Mainz University Medical Center. Mdr2−/−mice aged
11–15 weeks display advanced liver ﬁbrosis with a 4 to 5-fold increased
liver collagen content [25]. Wildtype and Mdr2−/−mice were housed
with a 12 h light/dark cycle with water and ad libitum normal diet. At
age 11–15 weeks Mdr2−/− mice were injected subcutaneously in the
neck, a site with suﬃcient subcutaneous space, with a suspension of
12.6 wt-% microspheres in 500 μL 0.4% carboxymethyl cellulose (CMC,
Aqualon high Mw, Ashland, pH 7.0–7.4). Microspheres contained either
5 wt-% HSA (n= 4), 3 wt-% pPB-HSA + 2 wt-% HSA (n= 16), 3 wt-%
pPB-MSA + 2 wt-% MSA (n= 8), or were empty (polymer only)
(n = 4). Groups of mice were sacriﬁced at 1, 3, 5 or 7 days for pPB-HSA
microspheres (n = 4 at each time point) and all other groups at day 7
after microsphere administration. Blood, liver and oﬀ target organs
were collected for further analysis.
2.5. ELISA
2.5.1. ELISA for pPB-HSA
pPB-HSA levels both in vitro (100 μL release buﬀer) and in vivo
(100 μL plasma or 1.4 mg/100 μL protein of liver, as determined with
Lowry assay) were assessed with our in-house developed sandwich
ELISA [22]. In short, the capture antibody α-pPB was diluted in coating
buﬀer (100 mM NaHCO3/33 mM Na2CO3 in water (pH 9.5) and in-
cubated overnight (100 μL, 6.5 mg/mL, 1:1000, custom prepared by
Charles Rivers, Den Bosch, The Netherlands) in a 96-well high protein
binding plate (Corning, New York, NY, USA). The plate was washed
extensively with PBS containing 0.5‰ Tween-20 (PBS-T) and blocked
with 200 μL 5 wt-% nonfat dry milk in PBS-T for 1 h. After washing,
100 μL sample was incubated for 2 h. The plate was washed again, and
the detection antibody goat α-HSA was applied (100 μL, 1:8000, ICN
Biomedicals, Zoetermeer, The Netherlands) for 1 h. The appropriate
HRP-conjugated secondary antibody (100 μL, 1:2000, DAKO, Santa
Clara, CA, USA) was applied for 1 h, and the substrate tetramethyl
benzidine (100 μL, R&D Systems, Minneapolis, MN, USA) was in-
cubated for 20 min after washing with PBS-T. The absorbance was
measured at 450 nm (THERMOmax microplate reader, Molecular De-
vices, Sunnyvale, CA, USA) after addition of 50 μL 2 N H2SO4.
2.5.2. ELISA for immunoglobulins
Plasma levels of immunoglobulins against pPB-HSA or pPB-MSA
were measured with an in-house developed ELISA. Either pPB-HSA or
pPB-MSA (100 μL, 10 μg/mL coating buﬀer) was incubated for 2 h at
room temperature in a high protein binding 96-well plate (Corning).
After extensive washing with PBS-T, non-speciﬁc binding sites were
blocked with 200 μL 5 wt-% nonfat dry milk in PBS-T for 1 h. Plasma
samples (100 μL plasma, diluted 1:100) were added for incubation of
1 h after washing with PBS-T. The plate was washed again and HRP-
conjugated anti-mouse immunoglobulins diluted in blocking buﬀer
(100 μL, 1:2000, DAKO) were incubated for 1 h. After washing with
PBS-T, the substrate tetramethyl benzidine (100 μL, R&D Systems) was
incubated for 20 min. The absorbance was measured at 450 nm after
addition of 50 μL 2 N H2SO4.
2.6. Quantitative real-time PCR
Total RNA from was isolated from livers using a Maxwell® LEV
simply RNA Cells/Tissue kit (Promega, Madison, WI, USA) according to
manufacturer's instructions. RNA concentrations were determined
using NanoDrop ND-100 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). The primers used include procollagen α1(I)
forward: 5′-TGACTGGAAGAGCGGAGAGT-3′; reverse: 3′-ATCCATCGG
TCATGCTCTCT-5′; PDGFβ-receptor forward: 5′-AACCCCCTTACAGCT
GTCCT-3′; reverse: 3′-TTCCTCTATTGCCCATCTC-5′; β-actin forward:
5′-ATCGTGCGTGACATCAAAGA-3′; reverse: 3′-ATGCCACAGGATTCCA
TACC-5′ (all Sigma-Aldrich). Quantitative real-time PCR analysis was
performed with 10 ng cDNA per sample according to manufacturer's
instructions (SensiMix™ SYBR kit, Bioline, Taunton, MA, USA) and was
analyzed by the ABI7900HT sequence detection system (Applied
Biosystems, Foster City, CA, USA). For each sample, the threshold cy-
cles (Ct values) were calculated with the SDS 2.3 software program
(Applied Biosystems) and mRNA expression was normalized for β-actin.
2.7. Immunohistochemistry
Cryosections of neck skin tissue were cut with a thickness of 4 μm
(CryoStar NX70 cryostat, Thermo Fisher Scientiﬁc), dried and ﬁxed
with acetone. Paraﬃn sections of livers were cut with a Leica Reichert-
Jung 2040 microtome (Leica Microsystems, Nussloch, Germany) with a
thickness of 4 μm. The sections were deparaﬃnized in xylene and
ethanol. All sections were rehydrated in PBS and were incubated for 1 h
with the primary antibody (goat anti-collagen I&III (both 1:200 + 5%
normal mouse serum (Southern Biotech, Birmingham, AL, USA)) or
rabbit anti-HSA (1:1500 (ICN Biomedicals)) at room temperature or
boiled in 10 mM Tris/1 mM EDTA (pH 9.0) for 15 min prior to over-
night incubation with rabbit anti-PDGFβ-receptor (1:50, Cell Signaling)
at 4 °C. Next, sections were incubated with the appropriate HRP-con-
jugated secondary antibody (1:100, DAKO, Santa Clara, CA, USA) for
30 min at room temperature, which were visualized with ImmPACT
NovaRED (both Vector, Burlingame, CA, USA). Hematoxylin counter-
staining was performed. Digital photomicrographs were captured at
400× magniﬁcation (Aperio, Burlingame, CA, USA).
2.8. Statistical analyses
At least 3 individual experiments were performed for the in vitro
microsphere characterization and these data are represented as
mean ± SD. All other data are represented as mean ± SEM. The
graphs and statistical analyses were performed with Graphpad Prism
version 6.0 (GraphPad Prism Software, Inc., La Jolla, CA, USA). The
diﬀerences between the groups were assessed by ordinary one-way
ANOVA followed by Bonferroni's multiple comparison test unless stated
otherwise. Basic pharmacokinetic modeling was performed with the
computer program Multiﬁt for non-linear curve-ﬁtting [26].
3. Results
3.1. In vivo pharmacokinetics of pPB-HSA
To determine the in vivo kinetics and tissue distribution of pPB-HSA,
all organs of mice with CCl4-induced acute liver ﬁbrogenesis were
collected and examined after a single intravenous injection with I125-
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labeled pPB-HSA. Ten minutes after injection, high amounts (65 ± 6%
of the dose) accumulated in the liver, expressing the PDGFβR [15],
whereas 15 ± 2% was still found in the plasma. A minor amount of the
remaining fraction was detected in the kidneys (2.6 ± 0.5%), spleen
(2.1 ± 1.0%), lungs (1.4 ± 0.5%), heart (0.9 ± 0.3%) and brains
(0.2 ± 0.1%). The active targeting of pPB-HSA to myoﬁbroblasts in
the ﬁbrotic liver has been shown in previous studies [18], and we
herewith conﬁrmed the steering of pPB-HSA to the organ with the
highest PDGFβR-expression (Fig. 1). Based on the plasma concentration
per milliliter at 10, 30 and 60 min after injection, the in vivo plasma
half-life was calculated to be approximately 40 min. Basic kinetic
modeling assuming 1-compartment kinetics further yielded a rough
estimate for the clearance of 58 μL/min and for the volume of dis-
tribution of 3 mL (Fig. S1 and Table S1).
3.2. Microsphere characterization
Microspheres containing pPB-HSA that ensure gradual and pro-
longed release into plasma for at least 7 days were developed. All mi-
crospheres were spherically shaped and had a smooth surface with little
to no pores, as shown with scanning electron microscopy (Fig. 2A, Fig.
S2). Laser diﬀraction analysis revealed that the two batches of protein-
loaded microspheres had similar particle size distributions with a
median particle size of around 25 μm, while polymer-only control mi-
crospheres were slightly smaller at all volume percentages (Table 1).
The polydispersity is expressed in the span (Eq. (1)), which is com-
parable to values found in earlier studies applying the same production
process [22]. Both protein-loaded microsphere formulations yielded
high encapsulation eﬃciencies of protein (Table 1) and showed low
burst release and sustained release in vitro for at least 14 days (Fig. 2B),
with a cumulative release after 14 days of 52% for pPB-HSA and 55%
for HSA. The slightly higher molecular weight of pPB-HSA (~74 kDa)
than HSA (67 kDa) did not aﬀect the release rate, with average values
of 4.5 ± 0.65%/day and 5.0 ± 0.29%/day, respectively.
3.3. Pharmacokinetic proﬁle of pPB-HSA released from microspheres in
vivo
The pPB-HSA microspheres were subcutaneously injected in the
neck of Mdr2−/− mice with advanced biliary liver ﬁbrosis. These
mice exhibit a profound increase in procollagen α1(I) and PDGFβR
gene expression as compared to normal mice (Fig. 3A, D), which is a
hallmark of ﬁbrosis [25]. The livers of these Mdr2−/− mice showed
characteristic deposition of collagen types I & III in the portal areas
particularly around the bile ducts (Fig. 3B) as a consequence of the
toxicity of accumulated of phosphatidylcholine in the hepatocytes, due
to the knock out of the transporter gene. Collagen deposition extended
into advanced portal to portal bridge formation in the parenchyma
(Fig. 3C). Accordingly, myoﬁbroblasts lining the ﬁbrotic bile ducts and
myoﬁbroblasts in the parenchyma expressed the PDGFβR (Fig. 3E, F).
The microsphere injection site was inspected for presence and ap-
pearance of microspheres that resided for 7 days at the injection site.
Clearly, during these 7 days the microspheres remained subcutaneous
(Fig. 4A) and the staining for HSA demonstrated that the microspheres
in vivo still contained protein after 7 days (HSA and pPB-HSA) (Fig. 4B,
C), as was expected from the in vitro release studies.
The pharmacokinetic proﬁle of the released pPB-HSA was de-
termined at 1, 3, 5 and 7 days after injection. We conﬁrmed sustained
release of pPB-HSA from the microspheres into the plasma up to 7 days
after injection reaching a steady state concentration of 44.9 ± 4.7 ng/
mL, which equals 2.4 ∗ 10−3 ± 0.3 ∗ 10−3%/mL based on the total
pPB-HSA content of the microspheres, within 1 day after injection and
remained constant for 5 days (Fig. 5A). The infusion rate of pPB-HSA
from the microspheres into the circulation was determined by multi-
plying this value with the clearance as estimated in the acute CCl4-
model, yielding an infusion rate of 0.2% per day. Interestingly, the
steady state concentration in plasma was 78.5 ± 10.9% lower at
7 days after injection than at day 5 (p < 0.0001, unpaired student t-
test).
In line with the PDGFβ-receptor expression, pPB-HSA was present in
the ﬁbrotic livers at all time points, reﬂecting a similar pattern as seen
in plasma, reaching a steady state concentration of 121 ± 28.3 ng/
Fig. 1. In vivo distribution of I125-labeled pPB-HSA in plasma, liver and oﬀ-target organs
at 10, 30 and 60 min after intravenous injection in mice with CCl4-induced acute liver
ﬁbrosis.
Fig. 2. Morphology and in vitro release of pPB-HSA from microspheres used in the
Mdr2−/− model for liver ﬁbrosis. (A) Representative scanning electron micrograph of
pPB-HSA microspheres after freeze-drying (1000× magniﬁcation). The empty micro-
spheres and microspheres containing HSA only exhibited similar morphology. (B)
Cumulative in vitro release of pPB-HSA and HSA from pPB-HSA microspheres and HSA
microspheres, respectively. Percentages are corrected for EE.
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liver within 1 day after injection (Fig. 5B). Similar to the observations
in plasma, a decline of 75.4 ± 5.3% in the pPB-HSA concentration was
detected in the livers after 7 days as compared to day 5 (p= 0.002,
unpaired student t-test). As expected, for both plasma and livers, the
control group with microspheres containing HSA only did not show any
presence of pPB-HSA.
The in vivo reduction in pPB-HSA levels 7 days after injection as
compared to earlier time-points was rather unexpected, as protein was
still present in the subcutaneous microspheres after 7 days (Fig. 4B and
C) and the in vitro data showed minimal burst release of pPB-HSA fol-
lowed by pseudo-zero order sustained release kinetics for 10 to 14 days
(Fig. 2B). To further investigate this phenomenon, plasma samples were
analyzed for the presence of antibodies against the albumin-based
carrier as this is not a mouse based protein, which might interfere with
our results. Indeed, the decline in pPB-HSA concentration at day 7
coincided with the induction of an antibody response against pPB-HSA
as compared to the empty microspheres as control group. Mice that
received microspheres containing HSA only also showed an induction
of the immune response to the same extent (Fig. 6A). This im-
munological reaction in these mice to the drug carrier was completely
absent when microspheres contained pPB-MSA, in which human serum
albumin was replaced with the mouse equivalent (Fig. 6B), as the re-
sponse was not exceeding background levels. The pPB-MSA micro-
spheres displayed similar size distribution (median 22 μm) and mor-
phology, and showed slightly faster in vitro release characteristics than
the microspheres containing the human albumin-based carrier (Fig. S3,
Table S2).
4. Discussion
Protein-based therapeutics including fusion proteins, such as pro-
tein-based drugs modiﬁed with targeting moieties, drastically increased
the treatment perspective for a wide variety of diseases [13,14,27]. In
the past decades, we developed various compounds enriched with
PDGFβ-receptor recognizing peptides (pPB) including the myoﬁbro-
blast-selective drug carrier PDGFβR-targeted human serum albumin
(pPB-HSA) [18]. We aim to apply this PDGFβR-targeted drug carrier,
when coupled to an eﬀective antiﬁbrotic compound, for the treatment
of chronic ﬁbrotic diseases. However, delivery of protein-based com-
pounds involves parenteral administration with consequent short-
lasting peak-concentrations and the need for frequent application,
posing a high burden to the potential patient. For eﬀective treatment of
such diseases the sustained release of therapeutics is essential. We
therefore developed a patient-friendly formulation providing sustained
release of protein therapeutics, which can be applied for protein con-
structs like pPB-HSA [22]. In the present study, we showed that pPB-
HSA was released from the subcutaneous polymeric microspheres into
the plasma and reached easily detectable levels in the ﬁbrotic liver,
where a steady state concentration was achieved within 1 day after
microsphere injection, which lasted for 5 days. A sudden decrease of
Table 1
Characteristics of microspheres with diﬀerent content as used in vivo in the Mdr2−/− model.
Formulation Protein load Particle size (μm ± SD) Span Encapsulation eﬃciency (%)
X10 X50 X90
pPB-HSA 3% pPB-HSA/2% HSA 4.4 ± 0.3 23.3 ± 1.5 59.5 ± 5.0 2.4 99
HSA 5% HSA 4.1 ± 0.2 27.6 ± 0.7 59.1 ± 1.2 2.0 81
Control – 2.5 ± 0.1 16.7 ± 1.2 43.9 ± 0.7 2.5 –
Fig. 3. (pro-) Collagen and PDGFβ-receptor expressions at mRNA (A and D, respectively) and protein level (B, C, E, F) in livers of Mdr2−/− mice. Of note, the staining (in red) is
observed in particular around the bile ducts (BD) (B and E, respectively) and in the parenchyma (C and F, respectively). Diﬀerences between groups were assessed by unpaired student t-
test. Arrows indicate ﬁbrous collagen bands.
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this concentration at day 7 was associated with antibody formation,
while antibody formation was prevented with the mouse albumin-based
carrier.
In an attempt to correlate the in vitro release of pPB-HSA from mi-
crospheres and the estimated in vivo infusion-rate, based on the steady
state concentration in plasma and the plasma clearance, we calculated
release rates of 4.5%/day and 0.2%/day, respectively. This yields ap-
proximately a 20-fold lower value in the in vivo situation. According to
Cardot and Tomic a linear in vitro - in vivo correlation only holds true
when either drug dissolution or release from the formulation are the
sole limiting factors for the systemic absorption [28]. In our studies,
multiple factors might have contributed to the limitation in the in vivo
infusion-rate of pPB-HSA, which will be discussed in more detail below.
The release of any drug from a subcutaneous depot occurs, when
dissolved, within the subcutaneous tissue (or hypodermis) pre-
dominantly by diﬀusion or convection. The anatomy and micro-
environment of the hypodermis can largely aﬀect the release and
transport of the drug [29]. Firstly, components of the subcutaneous
extracellular matrix including collagens, noncollagenous glycoproteins,
hyaluronic acid and chondroitin, heparan or dermatan sulfates can in-
terfere with locally dissolved drugs and impede their passage to the
circulation [30]. Such interference can happen in several ways, for
example by electrostatic or (non-) speciﬁc interactions with the re-
leased protein drug. This ultimately leads to the formation of charged
and/or large complexes that are unable to diﬀuse through the tissue
and consequently accumulate subcutaneously instead [31,32]. Also,
steric exclusion of the drug by the ECM can play a role, causing not only
limited diﬀusion, but might also inﬂuence the solubility of the protein
drug [33]. Secondly, other microenvironmental parameters including
the ionic composition and the pH of the injection site could limit pro-
tein absorption and stability [30,34]. Lastly, the uptake of drug in the
systemic circulation can be reduced due to degradation of the protein at
the injection site by the presence of proteases in the interstitial ﬂuid
[35].
After diﬀusion through the hypodermis, the released drug can reach
the systemic circulation via local semipermeable capillaries or by
lymphatic vessels, depending on the size of the protein. When the
sustained release formulation is subcutaneously injected, the pressure
in the interstitial ﬂuid is increased. As compensatory mechanism, the
local lymphatic ﬂow is stimulated in order to transport excess of ﬂuid
into the lymphatic system. Consequently, more macromolecules with a
diameter of up to 100 nm can be taken up, including pPB-HSA (which
we assume to have a diameter of< 25 nm [36]), and eventually these
molecules will be delivered to the bloodstream [37,38]. However, in
mice Wu et al. demonstrated a limited uptake of a similar protein, i.e.
bovine serum albumin, into the lymphatics following subcutaneous
injection, thereby causing lower drug plasma concentrations [39].
Another reason could be pre-systemic metabolism of the drug which
may occur in the draining lymphatics before reaching the circulation
[35]. Such parameters cannot be easily mimicked in vitro. In summary,
the in vitro studies are oversimpliﬁed as compared to the in vivo cir-
cumstances, which is clearly illustrated by our data. Recently, Kinnunen
et al. made the ﬁrst step towards an in vitro model that provides a better
representation of subcutaneous conditions [40] and this model poten-
tially yields better correlations with in vivo data in future studies.
Despite the expected discrepancy between the in vitro and in vivo
Fig. 4. Immunohistochemical staining for HSA of skin tissue samples at 7 days after injection. These samples were obtained at the subcutaneous injection site of the microspheres (MSP).
MSP contained either (A) no protein, (B) HSA or (C) pPB-HSA.
Fig. 5. Concentration of pPB-HSA in (A) plasma and (B) livers of Mdr2−/− mice that received microspheres (MSP) subcutaneously for either 1, 3, 5 or 7 days containing pPB-HSA or
HSA (only after 7 days) as determined with ELISA.
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release, we were able to show protein release and measured pPB-HSA at
a plasma steady state concentration of approximately 45 ng/mL during
5 days after injection (Fig. 5A), a sound result in view of the extremely
low in vivo half-life of 40 min. It is noteworthy that the calculated half-
life might be an overestimation, as the PDGFβR is most likely expressed
at a lower level in the acute CCl4-model than in the more clinical re-
levant Mdr2−/− model, mimicking many disease features seen in
human cirrhotic patients as well. Furthermore, a comparable con-
centration proﬁle was demonstrated in the ﬁbrotic liver as our target
organ, in which the PDGFβ-receptor was highly expressed, with a
steady state concentration of 121 ± 28.3 ng/liver within 1 day after
injection. Whether this concentration is suﬃcient to reach therapeutic
levels would depend on the potency of the attached antiﬁbrotic com-
pound.
Several studies showed the receptor selectivity of PDGFβR-targeted
constructs in diﬀerent animal models [18,41,42]. With the use of I125-
labeled pPB-HSA we conﬁrmed the speciﬁc accumulation of this par-
ticular construct in mice suﬀering from acute liver ﬁbrogenesis (Fig. 1).
Because of the conﬁrmation of the speciﬁc accumulation and the lim-
ited accumulation found in other organs (between 0.2 and 2.6%), we
did not consider any accumulation in oﬀ-target organs in the pharma-
cokinetic study in the Mdr2−/− model.
The rapid decline in plasma concentration after 7 days was not
anticipated, based on the pseudo zero-order in vitro release kinetics
(Fig. 2B) and the presence of protein in the microspheres in vivo 7 days
after injection (Fig. 4). We therefore hypothesized that this decline
might be induced by antibody formation in mice against the human
albumin-based carrier. Indeed, we demonstrated low antibody levels
during the ﬁrst 5 days, drastically increasing at day 7, which paralleled
the decline in plasma and liver levels of pPB-HSA (Figs. 5, 6A). As part
of the adaptive immune defense, B cells produce immunoglobulin an-
tibodies against an antigen, i.e. a foreign protein like pPB-HSA or HSA
in mice, upon prolonged exposure. The induced antibodies form com-
plexes with pPB-HSA or HSA that are ultimately eliminated by the
complement system [43].
Eventually, the induction of the immune response was successfully
circumvented by replacing human albumin with mouse albumin
(Fig. 6B), thereby creating a non-immunogenic drug carrier pPB-MSA.
This alternative approach proved that the antibody formation was di-
rected against the albumin part of pPB-HSA, and not against the pPB
targeting moieties or the crosslinking domain. We now constructed a
drug carrier that is compatible with our polymeric microsphere for-
mulation and applicable for chronic administration of proteins.
In conclusion, we demonstrated that PDGFβR-targeted albumin was
released in vivo from the subcutaneously injected polymeric micro-
spheres using hydrophilic multi-block copolymers composed of poly(L-
lactide) and poly ethylene glycol/poly(ϵ-caprolactone) blocks. pPB-HSA
was detectable in the plasma and in the ﬁbrotic liver up to 7 days after
injection. This implies that sustained release microsphere formulations
composed of these polymers are suitable for the parenteral delivery of
therapeutic proteins and might constitute a realistic option for future
application in chronic diseases such as liver ﬁbrosis, bearing in mind
that the origin of the potential therapeutic protein should be com-
plementary to the species used as model. Future research should focus
on pharmacodynamic aspects of the drug formulation, by incorporating
the PDGFβR-targeted albumin-based drug carrier coupled to an anti-
ﬁbrotic drug, thereby directing towards the clinical application of this
combined delivery system ensuring sustained release of targeted ther-
apeutic proteins.
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